Physician profile
Aaron Stuart Cetner
NPI 1982802245
$3,367.70
in general payments reported to CMS, 2019-2025
30 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $196 · 2021: $607 · 2022: $827 · 2023: $408 · 2024: $425 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998 · Education: $95.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.97 |
| Education | $95.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $685.78 | 2019-2023 | Ilumya, Winlevi |
| Abbvie INC. | $633.26 | 2019-2025 | Botox, Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $623.96 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $274.69 | 2019-2024 | |
| Genzyme Corporation | $194.24 | 2019-2024 | |
| Revance Therapeutics, INC. | $95.24 | 2024 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $92.47 | 2021-2024 | Libtayo, Dupixent |
| Kerecis Limited | $78.97 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Incyte Corporation | $65.92 | 2021-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $61.24 | 2022-2024 | Sotyktu |
| Ucb, INC. | $52.55 | 2020-2025 | Bimzelx |
| Pfizer INC. | $49.78 | 2019 | |
| Mayne Pharma Commercial LLC | $49.13 | 2019-2020 | |
| Mimedx Group, INC. | $41.32 | 2024-2025 | |
| Genentech USA, INC. | $41.24 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $40.58 | 2020-2021 | |
| Biofrontera INC. | $37.75 | 2021-2022 | |
| Leo Pharma INC. | $35.97 | 2021-2024 | Adbry |
| Kyowa Kirin, INC. | $35.78 | 2022-2023 | Poteligeo |
| Convatec INC. | $26.21 | 2025 | |
| Smith+Nephew, INC. | $20.91 | 2021 | |
| Dermavant Sciences, INC. | $18.54 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $18.27 | 2024 | Oracea |
| Arcutis Biotherapeutics, INC. | $16.77 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.44 | 2021 | |
| Prugen, INC. Pharmaceuticals | $14.74 | 2020 | |
| Merck Sharp & Dohme LLC | $14.05 | 2019 | |
| Allergan, INC. | $13.05 | 2022 | |
| Strata Skin Sciences, INC. | $11.47 | 2020 | |
| Journey Medical Corporation | $7.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Cetner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.